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Abstract
Background: The economic costs of treating patients with metastatic breast cancer have been examined in
several studies, but available estimates of economic burden are at least a decade old. In this study, we characterize
healthcare utilization and costs in the US among women with metastatic breast cancer receiving chemotherapy as
their principal treatment modality.
Methods: Using a large private health insurance claims database (2000-2006), we identified all women initiating
chemotherapy for metastatic breast cancer with no evidence of receipt of concomitant or subsequent hormonal
therapy, or receipt of trastuzumab at anytime. Healthcare utilization and costs (inpatient, outpatient, medication)
were estimated on a cumulative basis from date of chemotherapy initiation ("index date”) to date of disenrollment
from the health plan or the end of the study period, whichever occurred first. Study measures were cumulated
over time using the Kaplan-Meier Sample Average (KMSA) method; 95% CIs were generated using nonparametric
bootstrapping. Findings also were examined among the subgroup of patients with uncensored data.
Results: The study population consisted of 1444 women; mean (SD) age was 59.1 (12.1) years. Over a mean follow-
up of 532 days (range: 3 to 2412), study subjects averaged 1.7 hospital admissions, 10.7 inpatient days, and 83.6
physician office and hospital outpatient visits. Mean (95% CI) cumulative total healthcare costs were $128,556
($118,409, $137,644) per patient. Outpatient services accounted for 29% of total costs, followed by medication
other than chemotherapy (26%), chemotherapy (25%), and inpatient care (20%).
Conclusions: Healthcare costs-especially in the outpatient setting–are substantial among women with metastatic
breast cancer for whom treatment options other than chemotherapy are limited.
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Background
Breast cancer is the most common form of cancer
among women in the US, and the second leading cause
of cancer death [1]. It is estimated that one in every
eight women will develop breast cancer during their life-
time. In 2009, an estimated 192,370 women were diag-
nosed with breast cancer, and 40,170 women died from
the disease [1]. Approximately 6% of women with inci-
dent breast cancer have metastatic disease at initial pre-
sentation. An additional 20-40% of breast cancer
patients develop metastatic disease at some point
following diagnosis. Median survival in women with
metastatic breast cancer is about 18-24 months [2], but
many patients survive several years. Breast cancer is a
heterogeneous disease that is managed with a range of
treatment modalities. Approximately two-thirds of
breast cancer tumors are hormone-receptor positive (i.
e., express estrogen and/or progesterone receptors) [3],
and endocrine therapy is considered for these patients.
Between 20% and 30% of patients with breast cancer
have tumors that express HER-2/neu (HER-2), a tyro-
sine kinase growth factor receptor located on cell mem-
branes [4]. Targeted therapy with the monoclonal
antibody, trastuzumab (Herceptin
®), or the dual tyrosine
kinase inhibitor, lapatinib (Tykerb
®), in combination
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been reported to improve response rates in these
patients [5,6]. For patients with tumors that do not
express hormone receptors and those with HER-2 nega-
tive tumors, chemotherapy remains the main treatment
option [7]. Chemotherapy also is the primary treatment
modality for patients with rapidly progressive visceral
disease and those with hormone-receptor positive
tumors that do not respond or have become resistant to
endocrine therapy [8,9]. Multiple retrospective studies
[10-12] have reported that prognosis is poor among
these patients, which could result from the lack of ther-
apeutic options or inherent tumor aggressiveness [9].
Such findings underscore the high levels of unmet clini-
cal need and poor outcomes in this particular subset of
patients.
The economic costs of treating women with meta-
static breast cancer have been examined in several stu-
dies, but none to the best of our knowledge has
reported costs for patient subgroups defined on the
basis of tumor receptor expression and/or treatment
modality. Moreover, available estimates of the economic
burden of metastatic breast cancer are at least a decade
old. While a number of recent studies have evaluated
the economic burden of breast cancer, including all
women with this disease irrespective of stage, they did
not attempt to characterize disease burden separately
for those with metastatic versus earlier-stage disease
[13-15]. Disease stage may be a particularly important
consideration when evaluating the economic burden of
breast cancer as diagnosis, treatment, and follow-up–
and the costs thereof–w o u l db ee x p e c t e dt ov a r yb y
stage. In this study, we examine costs in women with
metastatic breast cancer receiving chemotherapy as their
principal treatment modality.
Methods
Data Source
Data for this study were obtained from a large private
health insurance claims database (Thomson Reuters
Marketscan Research Databases), and spanned the per-
iod January 1, 2000 through December 31, 2006. The
database is comprised of medical (i.e., facility and pro-
fessional service) and outpatient pharmacy claims from
employer-sponsored health insurance plans covering
more than 10 million persons annually, including
employees as well as their spouses and dependents. The
plans provide health benefits under a number of differ-
ent products, including fee-for-service and capitated
(full, partial) systems. Plan members reside throughout
the US; approximately 10% are aged 65 years or older.
Data available for each facility and professional-service
claim include date and place of service, diagnoses (in
International Classification of Diseases, Ninth Edition,
Clinical Modification [ICD-9-CM] format), procedures
performed/services rendered (in Health Care Financing
Administration Common Procedure Coding System
[HCPCS], ICD-9-CM, and Uniform Bill-92 [UB-92] for-
mats), and quantity of services (professional-service
claims only). Data available for each retail pharmacy
claim include the drug dispensed (in National Drug
Code [NDC] format), dispensing date, quantity dis-
pensed, and number of days of therapy supplied. All
claims include paid (i.e., reimbursed) amounts, including
patient deductibles, copays, and/or coinsurance
amounts; for hospital facility claims, paid amounts
include all services (including drugs) provided by the
institution during the hospital stay. Selected demo-
graphic and eligibility information is also available for
persons in the database, including age, sex, geographic
location, coverage type, and the start and end dates of
health insurance coverage. Patient-level data can be
arrayed chronologically to provide a detailed longitudi-
nal profile of all medical and pharmacy services
received.
All patient-identifying information is either fully
encrypted or removed, and the database is therefore
compliant with the Health Insurance Portability and
Accountability Act of 1996 and federal guidance on
Public Welfare and the Protection of Human Subjects.
Per the Code of Federal Regulations (45 CFR 46
§46.101), IRB review was not needed for a study of this
nature, since “... subjects cannot be identified, directly or
through identifiers linked to the subjects...” We had full
authorization to use the study database and full access
thereto for purposes of the research described herein.
Study Subjects
The study population consisted of all women, aged 18
years or older, who initiated chemotherapy for meta-
static breast cancer and had no evidence of concomitant
or subsequent receipt of hormonal therapy, or receipt of
trastuzumab at anytime (to limit attention to patients
with HER-2 negative disease). Presence of metastatic
breast cancer was ascertained on the basis of two or
more healthcare encounters with a diagnosis of breast
cancer (ICD-9-CM 174.x), plus two or more encounters
with a diagnosis of distant secondary malignant neo-
plasm (196.2, 196.5, 196.8, 197.X-199.0), between Janu-
ary 1, 2000 and December 31, 2006 [16,17]. Receipt of
chemotherapy was ascertained beginning 45 days prior
to first diagnosis of secondary malignant neoplasm
(through the end of follow-up), and was based on the
presence of medical claims with a HCPCS code for a
chemotherapy drug or a HCPCS, ICD-9-CM, or UB-92
code for administration of chemotherapy. A 45-day win-
dow was employed to capture instances where che-
motherapy might have been initiated prior to first
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claim. Date of initial receipt of chemotherapy was desig-
nated the “index date”.
Patients with two or more medical encounters with a
diagnosis of another malignant neoplasm (ICD-9-CM
140-172, 175-195, 200-208) 61 days or more before
their index date were excluded from the study popula-
tion, unless the site of the other neoplasm and the site
of metastases was the same (e.g., malignant neoplasm of
liver [155.0] and metastasis to liver [197.7]). Patients
who were not continuously eligible for comprehensive
health benefits during the six-month period preceding
their index date were dropped from the study sample to
ensure completeness in case ascertainment.
Follow-Up
Follow-up began on the index date and ended with dis-
enrollment from the health plan (in most instances, pre-
sumably due to death) or the end of the study period,
whichever occurred first.
Measures
Healthcare utilization was assessed by component of
care, including inpatient services, outpatient care, and
outpatient pharmacotherapy (i.e., drugs administered in
an outpatient setting or dispensed at a retail pharmacy).
Healthcare costs were estimated using paid (i.e., reim-
bursed) amounts, and were similarly characterized by
component of care as well as on an overall basis. Ana-
lyses of outpatient services were further stratified by set-
ting of care (emergency room, physician office, hospital
outpatient, home health/hospice/skilled nursing facility,
and other), and by type of service (e.g., evaluation and
management, laboratory, radiology diagnostic, etc.)
within selected settings, as feasible. Utilization and costs
of pharmacotherapy were tallied on an overall basis and
by selected medication groups.
Analyses
Characteristics of study subjects were examined, includ-
ing age, geographic region, payer, and prevalence of
selected comorbidities. Age, geographic region of resi-
dence, and payer type were ascertained as of the index
date. Comorbidities were ascertained based on the pre-
sence of diagnoses during the six-month pre-index
period.
Cumulative total healthcare utilization and costs were
estimated for each patient on a daily basis from index
date through the end of follow up. Mean levels of utili-
zation and cost of care were examined using Kaplan-
Meier Sample Average (KMSA) methods. Using this
technique, the follow-up period for each patient was
partitioned into one-month intervals. Kaplan-Meier esti-
mates of the probability of survival and continued health
plan enrollment to the beginning of each interval were
calculated. Expected utilization and associated costs of
care were then calculated as the sum of the Kaplan-
Meier estimates of the probability of survival to the
beginning of each interval multiplied by corresponding
estimates of utilization and costs respectively during the
interval conditional on survival to the beginning of the
interval [18]. Survival probabilities were calculated using
dates of disenrollment, which was assumed to occur as
a result of death; subjects who were observed through
the end of the study period (i.e., December 31, 2006)
were censored as of this date. Ninety-five percent confi-
dence intervals (95% CIs) for costs were calculated using
nonparametric bootstrapping [19]. Significance testing
was not performed, as there were no a priori hypoth-
eses. Cumulative component-specific healthcare costs,
and the distribution of total healthcare costs by compo-
nent, were estimated stratified by total cumulative cost
(i.e., USD < 25,000, 25,000-< 50,000, 50,000-< 75,000,
75,000-< 100,000, 100,000-< 200,000, and ≥200,000,
respectively). These analyses included only patients with
complete cost data (i.e., those not censored due to the
end of the study period, and thus for whom claims data
were available from date of chemotherapy initiation
through health plan disenrollment), as patients who
were censored at the end of the study period undoubt-
edly incurred costs subsequent to this date.
Results
Patient Characteristics
The study population consisted of 1444 women; num-
bers excluded due to failure to meet various study entry
criteria are provided in the Appendix (Additional File
1). Mean (SD) age was 59.1 (12.1) years; two-thirds of
patients were older than 55 years (Table 1). Mean (SD)
duration of follow-up was 532 (495) days (median = 366
days).
Healthcare Utilization
Sixty-four percent of patients were hospitalized at least
once during follow up; the average number of hospital
admissions was 1.7 per patient, and the mean number
of hospital days was 10.7 (Table 2). Over the entire
duration of follow-up, patients also averaged 58.9 physi-
cian office visits, 1.6 emergency room visits, 24.7 hospi-
tal outpatient visits, 5.5 home health/hospice/SNF visits,
and 12.5 other healthcare encounters. Use of outpatient
services was highest for radiology diagnostic services
(89%), followed by laboratory (85%), procedures typically
requiring anesthesia and/or sedation (69%), supplies
(58%), and nuclear medicine (49%) services. Patients
averaged 36.9 prescriptions during follow-up. Use of
pharmacotherapy was highest for the combined category
of analgesics, sedatives, and antidepressants (82%),
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Less than one-half of study subjects received cardiovas-
cular agents (45%), erythropoietin stimulating agents
(44%), gastrointestinal drugs other than anti-emetics
(47%), fluids and electrolytes (45%), bisphosphonates
(33%), and colony stimulating factors (33%).
Healthcare Costs
Mean (95% CI) cumulative healthcare costs averaged
$128,556 ($118,409, $137,644) from index date to the
end of follow-up (Figure 1). Outpatient services
accounted for 29% of total costs, followed by medication
other than chemotherapy (26%), chemotherapy (25%),
and inpatient care (20%) (Table 3). Among outpatient
services, costs were highest for diagnostic radiology
(19%) and radiation therapy (13%). Chemotherapy
accounted for one-half of all medication costs, followed
by colony stimulating factors (9%), erythropoietin stimu-
lating agents (8%), bisphosphonates (4%), anti-emetics
(4%), and pain, sedatives, and antidepressants (3%),
among others. Chemotherapy was most often adminis-
tered in physician offices (63%) and hospital outpatient
departments (20%).
Among patients with noncensored cost data (n = 957),
most (66%) had total costs less than $100,000 (Figures 2
and 3); outpatient and inpatient services accounted for
56% of total costs, while chemotherapy accounted for
23%. Among patients with total costs of $100,000 or
more (34% of 957), corresponding figures were 53% and
25%.
Discussion
Using a large health insurance claims database, we
examined healthcare utilization and costs among
patients with metastatic breast cancer receiving che-
motherapy as their principal treatment modality (i.e.,
with no evidence of receipt of concomitant hormonal
therapies or receipt of trastuzumab at anytime). Over a
mean duration of follow-up of about 18 months, total
medical-care costs averaged $128,556 per patient. Out-
patient services accounted for 29% of total costs, fol-
lowed by medication unrelated to chemotherapy (26%),
chemotherapy (25%), and inpatient care (20%). Use of
colony stimulating factors, erythropoietin stimulating
agents, bisphosphonates, anti-emetics, and the combined
category of analgesics, sedatives and antidepressants
accounted for most medication costs unrelated to che-
motherapy. In the outpatient setting, following services
for evaluation and management, the largest cost drivers
were associated with diagnostic imaging and radiation
therapy.
Previous studies have examined economic costs in
patients with metastatic breast cancer; from diagnosis to
death, total costs have been reported to range from
Table 1 Demographic and clinical characteristics of study
subjects with metastatic breast cancer receiving
chemotherapy
Parameter Value
n = 1444
Age (n, %)
18-34 20 1.4
35-44 139 9.6
45-54 358 24.8
55-64 473 32.8
≥65 453 31.4
Geographic region (n, %)
Northeast 176 12.2
Northcentral 399 27.6
South 784 54.3
West 85 5.9
Payer type (n, %)
HMO 56 3.9
Indemnity 524 36.3
PPO 459 31.8
POS 393 27.2
Other 12 0.8
Comborbidities (n,%)
Cerebrovascular disease 77 5.3
Coronary heart disease 152 10.5
Heart failure 26 1.8
Peripheral arterial disease 22 1.5
Diabetes 241 16.7
Kidney disease 29 2.0
Liver disease 100 6.9
Respiratory disease 547 37.9
None of above 634 43.9
Table 2 Healthcare utilization among patients with
metastatic breast cancer receiving chemotherapy
Mean
n = 1444
Inpatient
Acute hospital
Admissions (#) 1.7
Days (#) 10.7
Outpatient Services
Physician Office (#) 58.9
Emergency Room (#) 1.6
Hospital Outpatient (#) 24.7
Home Health (#) 5.5
Other (#) 12.5
Pharmacy Prescriptions (#) 36.9
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[16,17,20,21]. In prior studies, hospitalization has been
reported to be the largest component of total costs, ran-
ging from 33%-52% [16,17]. In our study, outpatient
care represented the largest component of total costs.
We urge caution, however, in comparing our findings
with those reported by others, due to differences in
study populations and methods. Of particular impor-
tance, our study is distinguished by the fact that we
focused on patients for whom chemotherapy was the
mainstay of treatment, and examined costs from initia-
tion of chemotherapy (rather than diagnosis, as is typi-
cally the case in other studies) to end of follow-up.
Other considerations include differences in expected
survival across patient subgroups, operational definitions
used to identify patients with metastatic disease, sources
of utilization and cost data (e.g., primary, secondary,
expert opinion), and how costs were measured (total vs
attributable only), among others.
As with any retrospective database analysis, our study
has limitations that should be considered when inter-
preting the results. For one, we used diagnosis and pro-
cedure codes from healthcare claims to identify women
with metastatic breast cancer who were receiving che-
motherapy. The accuracy of our case-finding methods is
in fact unknown. We note that in a validation study that
attempted to use ICD-9-CM diagnosis codes from Med-
icare claims data to identify patients with distant meta-
static disease, the sensitivity and positive predictive
value of such an approach were only 60% and 58%,
respectively, when compared against information from
the SEER program [22]. We suspect, however, that the
positive predictive value of our methods was high (i.e.,
Type 1 error rate was low), as we identified study sub-
jects on the basis of both diagnosis codes and evidence
of receipt of chemotherapy. Sensitivity, however, could
have been lower for a variety of reasons, including fail-
ure to use appropriate diagnosis codes for metastatic
disease when metastases were indeed present, and gen-
eration of claims for biopsies and/or procedures prior to
final pathological confirmation of clinical stage.
Second, while we sought to limit our attention to
patients with HER-2 negative disease, due to limitations
in study data, we had to infer HER-2 status based on
a b s e n c eo fe v i d e n c eo fr e c e i pt of trastuzumab. While
there might have been some HER-2 positive patients in
the study sample who had contraindications to or
refused trastuzumab therapy, we believe that most
patients with known HER2-positive disease would have
received trastuzumab, and therefore that exclusion of
patients with evidence of such therapy yielded a popula-
tion of patients with HER-2 negative disease.
T h i r d ,w em a yh a v ef a i l e dt oi d e n t i f ys o m ep a t i e n t s
who actually received chemotherapy, as administration
of these agents is often billed using codes that lack spe-
cificity. Also, it typically takes one year or more for new
products to receive a specific HCPCS code that can be
used to identify their use in healthcare claims databases.
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Figure 1 Cumulative costs among patients with metastatic breast cancer receiving chemotherapy.
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nonspecific (or miscellaneous) codes that may also be
used for other therapies.
Finally, due to HIPPA, vital status is not available in
most healthcare claims databases. We therefore used
health plan disenrollment as a proxy for death, as we
believe that few patients with metastatic breast cancer
are likely to change health plans, due to frequent limita-
tions on coverage of pre-existing conditions. We there-
fore did not treat health plan disenrollment as a
“censoring” event. If this assumption is incorrect, then
our cost estimates may be downwardly biased. We note,
however, that the median duration of follow-up in our
study (~12 months) is similar to reported median survi-
val (~9 months) in MBC patients with triple-negative (i.
e., HER2-negative, hormone-receptor negative, proges-
terone-receptor negative) disease, not all of whom
received chemotherapy [23].
Conclusions
In summary, our findings suggest that healthcare costs
among women with metastatic breast cancer who are
receiving chemotherapy are substantial, especially in the
outpatient setting. We believe that our study provides
important additional information on the economic bur-
den of metastatic breast cancer in a subset of patients
for whom treatment options other than chemotherapy
are limited.
Table 3 Cumulative cost of medical-care services among
patients with metastatic breast cancer receiving
chemotherapy
Mean (USD)(%)
n = 1444
Inpatient
Acute hospital 25,435 19.8%
Outpatient Services*
Emergency Room 736 0.6%
Physician Office/Hospital Outpatient
Evaluation and Management 2,851 2.2%
Laboratory 1,755 1.4%
Radiology Diagnostic 7,184 5.6%
Radiology Therapeutic 5,002 3.9%
Nuclear Medicine 891 0.7%
Procedures Requiring Anesthesia/Sedation 2,274 1.8%
Blood & Transfusion 176 0.1%
Physical & Occupational Therapy 318 0.2%
Medical & Surgical Supplies 841 0.7%
Mental health-care 58 0.0%
Other 10,362 8.1%
Subtotal 31,713 24.7%
Home Health/Hospice/Skilled Nursing 1,528 1.2%
Other 3,929 3.1%
Total 37,886 29.5%
Medication
Chemotherapy 31,651 24.6%
G-CSF 5,018 3.9%
ESAs 5,644 4.4%
Pain, sedatives, antidepressants 1,821 1.4%
Anti-infectives 332 0.3%
Anti-emetics 2,664 2.1%
Biphosphonates 2,842 2.2%
Gastrointestinal 538 0.4%
Electrolytes, Caloric, Water 67 0.1%
Cardiovascular 573 0.4%
Blood products & Anticoagulants 661 0.5%
Other 13,475 10.5%
Subtotal 65,260 50.8%
TOTAL 128,556 100.0%
*Other than medication administration
Total Follow-Up Costs (USD) (000s)
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Figure 2 Component costs of care among patients with
metastatic breast cancer, by total cost.
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Figure 3 Distribution of total costs of care among patients
with metastatic breast cancer, by total cost.
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